Losartan Potassium Tablet, Film Coated
Product Images NDC 72789-044

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72789-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789044 Label (72789044)

Label for Losartan Potassium USP 100 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc. The label includes dosing instructions, warning to keep out of reach of children, and packaging details for a 30-tablet bottle. The NDC is 72789-044-30, with lot number D22A84 and expiration date 11/2023. The label also features bilingual dosing instructions in English and Spanish and a QR code.*

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over 60 study months for atenolol and losartan potassium. The graph shows cumulative incidence increasing over time, with atenolol slightly higher. The text notes an adjusted risk reduction of 13% with losartan potassium and a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over 66 study months between Atenolol and Losartan Potassium. The graph illustrates a lower incidence of stroke in the Losartan Potassium group, showing an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

Figure 3 presents a comparative analysis of primary endpoint events within demographic subgroups, showing primary composite events and stroke rates (fatal and non-fatal) for Losartan Potassium versus Atenolol. The graph features patient counts, event rates (%), and hazard ratios with 95% confidence intervals across categories such as age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD).*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients experiencing an event over 48 months between Losartan Potassium and placebo groups. The graph highlights a risk reduction of 16.1% with Losartan Potassium compared to placebo, with the percentage of patients on the y-axis and time in months on the x-axis.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium, showing its molecular framework with characteristic rings and functional groups, including potassium ion (K+). The structure corresponds to the active ingredient in the Losartan Potassium pharmaceutical product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.